Publications

Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections.  Lead author: Rodrigo Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2173

Activity of Meropenem-Vaborbactam Tested against Burkholderia Species Isolates.  Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2757

Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales Isolates Collected in a Six-year Period (2017–2022).  Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2755

Evaluation of the VITEK®2 XL Antimicrobial Susceptibility Testing for Non-fermenter Gram-Negative Bacilli: The Importance of Continuing to Monitor Antimicrobial Susceptibility Testing (AST) Systems.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #568

Antimicrobial Activity of Aztreonamavibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022).  Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2146

In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020).  Lead author: Leonard Duncan, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2162

Evaluation of Isavuconazole Activity Against Non-fumigatus Aspergillus and Cryptic Aspergillus Species Causing Invasive Infections Worldwide.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #P2114

Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022.  Lead author: S.J. Ryan Arends, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2159

Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #P2113

Frequency, Antimicrobial Susceptibility, and Molecular Characterization of Carbapenem-Resistant Enterobacterales Stratified by United States Census Divisions: Results from the INFORM Program (2018–2022).  Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2802

Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Soft Tissue Infections (SSTIs) in US Medical Centers between 2017–2019 and 2022.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #1812

Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2020–2022).  Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2598

Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022).  Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #1292

Cefiderocol Activity Against Multidrug-resistant and Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020–2022).  Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2174

Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Multidrug-resistant Enterobacterales Clinical Isolates From United States Hospitals (2020–2022).  Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2172

Development and validation of an internal bioinformatic pipeline for 16S rRNA amplicon sequencing.  Lead author: Timothy B. Doyle, presented at ASM Microbe 2023, June 15-19, Houston, TX, USA

Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Positive Organisms: A Report from the SENTRY Antimicrobial Surveillance Program.  Lead Author: Cecilia G. Carvalhaes, presented at ASM Microbe, June 15-19, Houston, TX, USA

Antimicrobial Susceptibility Testing for β-lactam/β-lactamase Inhibitor Combination Agents Against Enterobacterales Isolates Harboring β-lactamase Resistance Genes from North and Latin America: Comparison of VITEK® 2 AES and Broth Microdilution Methods.  Lead Author: Cecilia G. Carvalhaes, presented at ASM Microbe 2023, June 15-19, Houston, TX, USA

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program by JM Maher, MD Huband, CG Blankers, S Puttagunta, SI Aronin, and M Castanheira in J Antimicrob Chemother 78(4): 2023, dkad099.

Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020) by SJR Arends, D Butler, N Scagarella-Oman, M Castanheira, and RE Mendes in Antimicrob Agents Chemother 67(4): 2023, e0152522.

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Pneumonia in Europe and United States: Results from the SENTRY Program (2019–2021). Lead author: Helio Sader. ECCMID 2023, April 15-18, Copenhagen.

Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Negative Organisms: A Report from the SENTRY Antimicrobial Surveillance Program. Lead author: Mariana Castanheira. Presented at ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of Omadacycline and Comparator Agents Against 485 Infrequently Encountered Bacterial Pathogens from the SENTRY Surveillance Programme. Lead author: Michael Huband. ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions. Lead Author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

Comparison of In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020–2021). Lead author: Dee Shortridge, ECCMID 23, April 15-18, Copenhagen.

Cefiderocol In Vitro Activity Against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020–2021). Lead author: Rodrigo Mendes. ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of Manogepix and Comparators against 610 Infrequently Encountered Yeast and Mould Isolates from the SENTRY Surveillance Program (2017–2022). Lead author: Michael Huband, ECCMID 2023, April 15-18, Copenhagen.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Rezafungin Activity against Candida and Aspergillus Isolates Causing Invasive Infections in European Medical Centres (2019–2021). Lead author: Cecilia Carvalhaes. ECCMID 2023, April 15-18, 2023, Copenhagen.

Activity of Cefiderocol and Comparator Agents against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalised with Pneumonia in European Medical Centres (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

In vitro Activity of Novel Compound RG6006 Against Clinical Isolates of Acinetobacter baumannii-calcoaceticus complex in the Presence of 20% Human Serum. Lead author: Dee Shortridge. Presented at ECCMID 2023, April 15-18, 2023, Copenhagen.

In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019–2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of Bacteriophage Cocktail Tested Against Pseudomonas aeruginosa Cystic Fibrosis Isolates. Lead author: Timothy Doyle. ECCMID, April 15-18, Copenhagen.

VITEK2 Advanced Expert System β-Lactam Resistance Phenotyping Compared to Whole Genome Sequencing in Enterobacterales Isolates from European Medical Centres. Lead author: Cecilia Carvalhaes. Presented at ECCMID 2023, April 15-18, Copenhagen.

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Bloodstream Infections from Europe, Asia, and Latin America (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

Trends on the Activity of Mould-active Agents Against Aspergillus fumigatus Clinical Isolates With and Without Cyp51 Alterations
from Europe and North America (2017–2021). Lead author: Cecilia Carvalhaes. Presented at ECCMID 23, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against European Enterobacterales, Including Carbapenem-Resistant Isolates, From the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID, April 15-18, Copenhagen.

Rezafungin Activity against Candidemia isolates collected from European medical centres (2019–2021). Lead author: Cecilia Carvalhaes. Presented at ECCMID 2023, April 15-18, 2023, Copenhagen.

Enterobacter hormaechei Carrying blaNDM Predominates Among Carbapenem-resistant Enterobacter spp. Collected During the SENTRY Antimicrobial Surveillance Program (2016–2021). Lead author: Hank Kimbrough.

Bloodstream Infections in Europe and United States: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Helio Sader. Presented at ECCMID 2023, April 15-18, Copenhagen.

Comparison of Cefiderocol and Cefepime-Taniborbactam Activities against Resistant Subgroups of Enterobacterales and Pseudomonas aeruginosa, and Cefiderocol and Sulbactam-Durlobactam Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. Lead Author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against US Enterobacterales, Including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID, April 15-18, Copenhagen.

Recent Increase in Fluconazole-Nonsusceptible Candida parapsilosis in a Global Surveillance with the Expansion of the Erg11 Y132F genotype and a Rapid Detection Method to Detect This Alteration. Lead Author: Mariana Castanheira, ECCMID 2023, April 15-18, Copenhagen.

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21) by HS Sader, M Castanheira, JH Kimbrough, V Kantro, RE Mendes in J. Antimicrob. Chemother. 5(3):2023, dlad032.

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug resistant Enterobacterales from United States Medical Centers (2018−2022) by HS Sader, RE Mendes, L Duncan, JH Kimbrough, CG Carvalhaes, and M Castanheira in Diagn Microbiol Infect Dis 2023; 106, 115945.

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific by CG Carvalhaes, PR Rhomberg, MD Huband, MA Pfaller, and M Castanheira in J of Fungi 2023; 9, jof9020241.

Contemporary molecular epidemiology of Escherichia coli causing urinary tract infections in the United States and in vitro activity of tebipenem and comparators against various genetic subsets (2018-2020) by RE Mendes, SJ Ryan Arends, JM Streit, I Critchley, N Cotroneo, and M Castanheira in Microbiol Spectrum 2023; 11(1), 2057-22.

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with complicated urinary tract infections by HS Sader, CG Carvalhaes, MD Huband, RE Mendes, and M Castanheira in Eur J Clin Microbiol Infect Dis. 2023; 42(2), 453-459.